Beneficial phytoestrogenic effects of resveratrol on polycystic ovary syndromein rat model

Abstract

Aims

The effective treatment of polycystic ovary syndrome (PCOS)-related hormonal disorders necessitates the development of novel treatment strategies. Resveratrol is found in certain food products, and is known to exhibit phytoestrogen properties. The present study was to assess whether resveratrol exhibits beneficial phytoestrogenic effects and associated hormonal modulation in a rat model of PCOS.

Materials and methods

This model was established by administering oral letrozole to female Sprague–Dawley (SD) rats prior to randomizing them into control, model and resveratrol treatment groups (40, 80, or 160 mg/kg). Animals were treated for 30 days, after which time ovarian tissues were collected and evaluated via hematoxylin and eosin staining. In addition, serum levels of estradiol and adiponectin were assessed via ELISA, and ovarian expression of nesfatin-1 and aromatase was assessed through RT-PCR and western blotting.

Results

We found that resveratrol administration was associated with increased levels of plasma adiponectin and estradiol levels and restoration of normal ovarian morphology in PCOS model animals. In addition, this treatment was linked to the increased ovarian expression of nesfatin-1 and aromatase at the RNA and protein levels.

Conclusions

Together things findings suggest that resveratrol may represent an effective tool for treating PCOS owing to its phytoestrogenic properties.

摘要

目的：多囊卵巢综合征(PCOS)相关激素紊乱的有效治疗需要开发新的治疗策略。白藜芦醇存在于某些食品中, 已知具有植物雌激素特性。本研究旨在评估白藜芦醇在多囊卵巢综合征大鼠模型中是否表现出有益的植物雌激素效应和相关的激素调节。

材料和方法：用来曲唑给雌性SD大鼠灌胃, 然后随机分为对照组、模型组和白藜芦醇治疗组(40, 80,160 mg/kg), 建立该模型。动物治疗30天后, 收集卵巢组织并进行苏木精-伊红染色。采用ELISA法检测血清雌二醇和脂联素水平, RT-PCR和Western blotting法检测卵巢组织中Nesfatin-1和芳香化酶的表达。

结果：我们发现白藜芦醇的应用与PCOS模型动物血浆脂联素和雌二醇水平的升高以及卵巢正常形态的恢复有关。此外, 在RNA和蛋白质水平上, 这种治疗与提高卵巢中Nesfatin-1和芳香化酶的表达有关。

结论：综上所述, 研究结果表明, 由于白藜芦醇的植物雌激素特性, 白藜芦醇可能成为治疗多囊卵巢综合征的有效药物。

Keywords:

• Resveratrol
• phytoestrogenic
• polycystic ovary syndrome (PCOS)

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work was supported by the Natural Science Foundation of Shandong Province [No. ZR2019MH117] and the Special fund for clinical research of Chinese Medical Association [No. 18010140743].